President & CEO
Kristine Ball brings to Antiva over 20 years of executive experience in the biopharma industry. Kristine has held key roles in building multiple successful biopharma companies that developed FDA approved medicines. Kristine has also led numerous corporate transactions throughout her career including multiple IPOs, M&A transactions, pharmaceutical partnerships and other private and public financings. Prior to Antiva, Kristine served as Chief Executive Officer of Soteria, Inc. from 2020 to 2022, where she raised the company’s series A round of financing, recruited the management team and set the strategic direction of the company. From 2017 to 2022, Kristine served as Senior Vice President of Corporate Strategy and Chief Financial Officer of Menlo Therapeutics, Inc., until the company’s merger with Foamix. At Menlo, Kristine was responsible for leading all non-R&D functions including strategic planning, corporate development, commercial, human resources, legal, finance and IT. She led Menlo’s initial public offering and the cross-functional team responsible for closing the merger with Foamix. Prior to Menlo, Kristine held executive finance positions at Relypsa, Inc. (acquired by Galenica), KAI Pharmaceuticals, Inc. (acquired by Amgen) and Exelixis, Inc. Kristine began her career in Ernst & Young’s life sciences audit practice. Kristine serves as a member of the board of directors of Atreca, Inc. and also served on the board of directors of Forty Seven Inc. prior to the company’s acquisition by Gilead. Kristine holds a B.S. from Babson College.
Chief Medical Officer
Elaine Chien, MD, FACOG is a board-certified and licensed OB/GYN physician who brings more than 25 years of clinical and biopharmaceutical industry experience to Antiva, including leadership roles on multidisciplinary teams supporting advancement of early to late-stage clinical programs through approval. Prior to joining Antiva, from 2019 to 2023 she held roles of increasing responsibility at Mirum Pharmaceuticals, ultimately serving as Vice President, Clinical Development and Medical Safety with responsibility for overall strategic and executional oversight of all development programs for the company’s clinical-stage asset as well as global medical safety and pharmacovigilance for all of Mirum’s commercial and clinical stage assets. Over Elaine’s career, she has been a key contributor to several US and EU drug approvals, in women’s health and other indications. At Mirum, she was the medical safety lead on multiple sNDAs, an MAA and a Type II Variation for Livmarli® for the treatment of Alagille Syndrome (ALGS) and Primary Familial Intrahepatic Cholestasis (PFIC). Prior to Mirum, Elaine was the global clinical development lead for the Myfembree® pivotal Phase 3 endometriosis program at Myovant Sciences, and the medical safety lead at Clovis Oncology on the NDA and MAA for Rubraca® for BRCA-positive ovarian cancer. Elaine holds a Bachelor of Arts in Economics and an MD from Northwestern University, completed her OB/GYN residency at the Los Angeles County + University of Southern California medical center, and has been a Diplomate of the American Board of Obstetrics and Gynecology since 2005.
Senior Vice President of Pharmaceutical Development and Manufacturing
Raju Gadiraju, PhD brings more than 25 years of pharmaceutical development and manufacturing experience to Antiva, including work on various dosage forms and technologies and developing products from pre-candidate nomination to late-stage development. Most recently, Raju was Senior Director at Nektar Therapeutics, where he managed global product development and clinical supplies management teams. During his 17 years at Nektar, Raju set up strategic partnerships for overall supply chain, supported global regulatory submissions and several successful partnership deals. He received his Bachelor’s degree in Pharmacy from Kakatiya University in India, a Master’s degree in Pharmaceutics from Jadavpur University in India, and a Ph.D. in Pharmaceutics from University of Iowa. He also serves as adjunct professor at University of Pacific and in leadership roles in professional organizations.
Senior Vice President of Nonclinical Development & Global Health Strategy
Sarah Walter, PhD came to Antiva from Labrys Biologics where she oversaw Preclinical Development and Scientific Affairs until their acquisition by Teva Pharmaceuticals in 2014. Prior to Labrys, Sarah worked at KAI Pharmaceuticals for 9 years where she was involved in multiple stages of development for their lead program,
Vice President of Project Management & Strategic Initiatives
Dr. Wilson is a seasoned biopharmaceutical industry executive with more than 25 years of experience leading and managing complex global research and development programs. As Vice President of Project Management and Strategic Initiatives, she will be charged with establishing and leading Antiva’s program management function, aligning and mobilizing cross-functional teams to drive execution of the company’s development programs. Most recently, Dr. Wilson served as Vice President, Program, Portfolio and Alliance Management (PPAM) at Revolution Medicines. During this time, she provided PPAM leadership for the company’s portfolio of oncology-focused research and development assets from startup through rapid expansion of its clinical-stage portfolio. Dr. Wilson also provided key contributions to KAI Pharmaceuticals leading up to its July 2012 acquisition by Amgen, serving as the company s Vice President, Project Management and Project Leader for
Senior Virology Adviser
Michael Cordingley, PhD has more than 30 years of experience in pharmaceutical research. Mike brings to Antiva a wealth of experience in virology and innovative drug discovery and development across multiple therapeutic areas. He is currently CSO at Transposon Therapeutics, a clinical stage biotechnology company developing novel therapies for neurodegenerative, autoimmune and age related diseases Previously, he was President of Research and Site Head for Boehringer Ingelheim in Canada and a member of the global executive leadership team for Boehringer Ingelheim Research and Development. Mike has also held positions in Bristol Myers-Squibb and Merck Research Laboratories and has successfully led research organizations and teams working in numerous antiviral indications including HIV, HCV, human papilloma, and respiratory virus infections. Mike holds a PhD from the MRC Institute of Virology, University of Glasgow and an MA in Genetics from the University of Cambridge, England.